Alliance for Pandemic Preparedness

October 16, 2020

Repurposed Antiviral Drugs for COVID-19 Interim WHO SOLIDARITY Trial Results

Category:

Topic:

Keywords (Tags):

[Pre-print, not peer reviewed] Interim results for the original four drugs in the WHO Solidarity trial indicated that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens did not appear to reduce mortality, initiation of ventilation, or duration of hospital stay. Out of 11,266 adults in 30 countries who were randomized, 1,253 deaths were reported. Kaplan-Meier analysis of 28-day mortality was 12% (39% if already ventilated at randomization, 10% otherwise). Death rate ratios were: remdesivir RR=0.95, hydroxychloroquine RR=1.19, lopinavir/ritonavir RR=1.00, and interferon RR=1.16. 

WHO Consortium et al. (Oct 15, 2020). Repurposed Antiviral Drugs for COVID-19 Interim WHO SOLIDARITY Trial Results. Pre-print downloaded Oct 16 from https://doi.org/10.1101/2020.10.15.20209817